The Liver Meeting 2019-Rationale for Surveillance in HCC for Patients with NASH/Metabolic Syndrome

Rationale for Surveillance in HCC for Patients with NASH/Metabolic Syndrome

Video Transcription

Video Summary

In the video transcript, Dr. Elisabetta Bugianesi discusses the rationale for surveillance in hepatocellular carcinoma (HCC) for patients with NASH and metabolic syndrome. She highlights the importance of identifying high-risk patients and factors influencing the utility of surveillance, such as diagnostic tests and treatment availability. Dr. Bugianesi explains the progression from NAFLD to HCC, emphasizing the impact of obesity, insulin resistance, genetic modifiers, and lifestyle factors. She discusses the challenges of non-invasive tests for stratifying HCC risk in NAFLD and the need for clear epidemiological data and reliable tools for surveillance. Lifestyle interventions, like the Mediterranean diet and physical activity, are recommended for preventing HCC in NAFLD patients. Additionally, the potential role of drugs like metformin and statins in reducing HCC risk is mentioned.

Asset Caption

Presenter: Elisabetta Bugianesi

Keywords

surveillance in hepatocellular carcinoma

NASH

metabolic syndrome

high-risk patients

diagnostic tests

treatment availability